Human Osteoprotegerin/TNFRSF11B Antibody

Name: Human Osteoprotegerin/TNFRSF11B Antibody
Brand: R&D Systems
SKU: MAB805-500
Rating: 4 (1 reviews)

Catalog #: MAB805
4 Citations 1 Review Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB805-SP
MAB805-100
MAB805-500

Request a Quote Bulk Orders

Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/ TNFSF10-induced Cyto-toxicity and Neutral-ization by Human Osteoprotegerin/ TNFRSF11B Antibody.

1 Image

Product Details

Citations (4)

FAQs

Supplemental Products

Reviews (1)

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Osteoprotegerin/TNFRSF11B Antibody Summary

Species Reactivity

Human

Specificity

Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse Osteoprotegerin is observed.

Source

Monoclonal Mouse IgG₁ Clone # 69146

Purification

Protein A or G purified from ascites

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Osteoprotegerin/TNFRSF11B
Glu22-Leu401
Accession # AAB53709

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize Osteoprotegerin/TNFRSF11B-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND₅₀) is typically 0.15-0.3 µg/mL in the presence of 0.1 µg/mL Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera, 50 ng/mL Recombinant Human TRAIL/TNFSF10, and 0.5 µg/mL actinomycin D.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/ TNFSF10-induced Cyto-toxicity and Neutral-ization by Human Osteoprotegerin/ TNFRSF11B Antibody. In the presence of the metabolic inhibitor actinomycin D (0.5 µg/mL), Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (Catalog # 805-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/ TNFSF10 (50 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Osteoprotegerin/TNFRSF11B Monoclonal Antibody (Catalog # MAB805). The ND₅₀ is typically 0.15-0.3 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Reconstitution Buffer Available

Reconstitution Buffer 1 (PBS)

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Osteoprotegerin/TNFRSF11B

Osteoprotegerin is a member of the TNF receptor superfamily expressed by many cell types. It exists in soluble monomeric and dimeric forms as a decoy receptor for its ligands, TRANCE and TRAIL. Osteoprotegerin functions as an antagonist to RANKL-induced osteoclastogenesis and bone resorption.

Entrez Gene IDs

4982 (Human); 18383 (Mouse)

Alternate Names

OCIF; OCIFMGC29565; OPG; OPGtumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin; TNFRSF11B; TR1; tumor necrosis factor receptor superfamily, member 11b

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human Osteoprotegerin/TNFRSF11B Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

4 Citations: Showing 1 - 4
Filter your results:

Filter by:

Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
Mol. Cancer Ther., 2007-12-07;6(12):3219-28.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Authors: Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI
Arthritis Rheum., 2006-05-01;54(5):1463-72.
Species: Human
Sample Types: Cell Lysates, Whole Tissue
Applications: IHC, Western Blot
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Authors: Mandelin J, Li TF, Hukkanen M, Liljestrom M, Salo J, Santavirta S, Konttinen YT
J. Rheumatol., 2005-04-01;32(4):713-20.
Species: Human
Sample Types: Whole Tissue
Applications: IHC
Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.
Authors: Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhao H, Resende C, Castelao W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M
Clin. Exp. Rheumatol., 2005-03-01;23(2):185-92.
Species: Human
Sample Types: Whole Tissue
Applications: IHC